KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Receivables - Net (2016 - 2026)

Bristol Myers Squibb has reported Receivables - Net over the past 18 years, most recently at $9.4 billion for Q1 2026.

  • Quarterly Receivables - Net fell 13.27% to $9.4 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $9.4 billion through Mar 2026, down 13.27% year-over-year, with the annual reading at $11.4 billion for FY2025, 6.21% up from the prior year.
  • Receivables - Net was $9.4 billion for Q1 2026 at Bristol Myers Squibb, down from $11.4 billion in the prior quarter.
  • Over five years, Receivables - Net peaked at $11.4 billion in Q2 2024 and troughed at $8.5 billion in Q1 2022.
  • The 5-year median for Receivables - Net is $10.4 billion (2024), against an average of $10.4 billion.
  • Year-over-year, Receivables - Net rose 18.13% in 2023 and then dropped 13.27% in 2026.
  • A 5-year view of Receivables - Net shows it stood at $9.9 billion in 2022, then rose by 10.47% to $10.9 billion in 2023, then fell by 1.59% to $10.7 billion in 2024, then rose by 6.21% to $11.4 billion in 2025, then fell by 17.93% to $9.4 billion in 2026.
  • Per Business Quant, the three most recent readings for BMY's Receivables - Net are $9.4 billion (Q1 2026), $11.4 billion (Q4 2025), and $11.4 billion (Q3 2025).